Reuters - Business Video Online

Shire’s new drugs defence to AbbVie

Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business. Sonia Legg reports